Regional Analysis

Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market: Regional Insights

Based on geography, the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period due to the rise in NASH-affected population and increase in diabetic and obese population in the region, especially in the U.S. NASH is an advanced form of non-alcoholic fatty liver disease (NAFLD). For instance, according to the American Liver Foundation, NAFLD is a most common chronic liver condition in the U.S. More than 25% of adults in the U.S. have NAFLD. Of those with NAFLD, more than 20% have NASH (5% of adults in the U.S.). This in turn has increased the demand for NASH therapeutics and diagnostics in the U.S.

Europe is also expected to witness significant growth in the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market owing to the increase in prevalence of diabetes, rise in NASH-affected population, and rise in demand for safe/effective therapeutics and diagnostics in the region. For instance, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), NASH prevalence is 10 million, or around 18% of the EU population and its prevalence in European countries is expected to increase by around 40% by 2030. It is becoming the leading cause for liver transplants. This in turn is driving the market growth.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa